Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.
about
Basic concepts in opioid prescribing and current concepts of opioid-mediated effects on drivingAbuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users.Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrenceThe Clinical Applications of Extended-Release Abuse-Deterrent Opioids.Correlates and Consequences of Opioid Misuse among High-Risk Young Adults.Denial of prescription analgesia among people who inject drugs in a Canadian settingSCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program.A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of OxycodoneSatisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine Compared with Oral Opioid Medications in the Usual Care of Osteoarthritis Pain.A practical and ethical solution to the opioid scheduling conundrum.Self-management of pain among people who inject drugs in Vancouver.Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?Electronic opioid risk assessment program for chronic pain patients: barriers and benefits of implementation.Alternative routes to oral opioid administration in palliative care: a review and clinical summary.Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.Abuse-deterrent formulations: part 2: commercial products and proprietary technologies.Opioid abuse-deterrent strategies: role of clinicians in acute pain management.Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.Drug Formulation Advances in Extended-Release Medications for Pain Control.Rethinking chronic pain in a primary care setting.Opiate Injection-associated Infective Endocarditis in the Southeastern United States.Management of Patients on Abuse-Deterrent Opioids in the Ambulatory Surgery Setting.Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone/Acetaminophen in Recreational Users of Prescription Drugs.Self-management of buprenorphine/naloxone among online discussion board users.Designing a tool allowing for a standardized assessment of resistance to drug diversion.The implications of tamper-resistant formulations for opioid rotation.Advances in the delivery of buprenorphine for opioid dependence.Acute Sensorineural Hearing Loss After Abuse of an Inhaled, Crushed Oxymorphone Extended-Release Tablet.A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
P2860
Q24629914-A83E8935-2B6E-4C0B-8476-F0DD38F01421Q33633597-F6FFABE3-4798-4F5C-BB2F-EF8CFE0D6C78Q33938740-BAF374B3-A349-42E6-9D04-BF345D4F07E5Q34530594-F66E5919-6B78-41F6-9994-0A09AA7D0F1AQ34652214-4CE5EBB5-2883-4B49-8179-5EE9BE9A1274Q36315014-D60004CB-B234-41C4-9998-5FC29D9816E4Q36478691-EF3E481A-8E1A-4AAE-B64E-75F106AE6BD5Q36972164-D20E18E2-0C86-4D73-92DA-63C94A9AFCB9Q37048823-EFAAB9E6-ACBC-41E8-B152-4C26CBC1011BQ37390980-E9718DF5-A44E-4495-935E-86E810342547Q37656409-9857649E-5E39-4EF7-B8A2-82523A8E08C6Q38068507-59366A5C-0427-4DEC-A2FF-3C9C1A0BDD45Q38166451-4FD8B277-19E6-469A-8929-05F48E2DF86AQ38226298-0C63F0E7-6435-4497-9BE8-14253E5E7383Q38241632-73ED0807-C100-47C7-B0CD-FA645CE67437Q38271152-E3EA00E2-5405-44C1-9FD7-F278A8244AD9Q38657470-2AFE8C8C-3F76-4E4A-B2C9-ADBB7BD5FD68Q38799636-DE5B7D1B-019F-4D65-8AB7-56A0D0E95A25Q38809652-9E8DF50D-9A0C-407F-A970-C8D86A4919D5Q38831661-156C4E24-FBD3-4E71-88D8-9D41CB8621BCQ39028794-CABFB3B2-7F44-4474-864C-A8593829B8D5Q39157561-888115DF-263D-494C-8462-A79799806996Q40610091-53BA16C2-D1B2-49C3-B364-02BC5CDD6380Q41441944-10F4F932-0C4B-4509-A9F6-5A06189F911AQ43317466-AF5FD72C-3230-43D7-AC3F-DF7D256CA8E9Q44336529-7D31046E-064B-47B3-9098-EA9C708B7736Q45946172-BF6F41E9-1B0F-4322-B468-12BF98CC92D6Q48108807-240CEBCD-C642-4BCF-B90B-10ECF4CA4074Q52307891-00B9E2CA-95AB-4D7C-BA43-058FCC3A11A0
P2860
Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Strategies to reduce the tampe ...... logic deterrents to tampering.
@ast
Strategies to reduce the tampe ...... logic deterrents to tampering.
@en
type
label
Strategies to reduce the tampe ...... logic deterrents to tampering.
@ast
Strategies to reduce the tampe ...... logic deterrents to tampering.
@en
prefLabel
Strategies to reduce the tampe ...... logic deterrents to tampering.
@ast
Strategies to reduce the tampe ...... logic deterrents to tampering.
@en
P2093
P2860
P1476
Strategies to reduce the tampe ...... logic deterrents to tampering.
@en
P2093
Patricia Bruckenthal
Robert L Barkin
Steven P Stanos
P2860
P304
P356
10.1016/J.MAYOCP.2012.02.022
P407
P577
2012-07-01T00:00:00Z